Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses natural remedies and nanoparticle formulations for alopecia management and reports no new clinical results, emphasizing potential benefits of herbal treatments over synthetic therapies.

In this study, researchers observed that alopecia areata patients showed higher Th1 and Th2 responses against specific melanogenesis-related protein epitopes, suggesting a role in disease activity and potential targets for diagnostics and therapies.

Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

This study found that sulfated CCK octapeptide reduces psoriasis-like skin inflammation in mice, suggesting a new pathophysiological role for CCK in regulating epidermal inflammation.

This study found that Th22 cells and their cytokine IL-22 may play an important role in the pathogenesis of systemic lupus erythematosus and could serve as bioindicators for monitoring disease severity.

This study found that intracellular Toll-like receptors were significantly up-regulated in peripheral blood mononuclear cells of alopecia areata patients, suggesting a potential role in inflammatory signaling and pathogenesis.

This review found that autoimmune damage is a key factor in alopecia areata, noting its comorbidity with other diseases and the potential of Janus kinase inhibitors in treatment.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

In this study, researchers developed a dissolvable microneedle patch combining HA-TEMPO and Portulaca oleracea L.-derived nanoparticles, which effectively reduced oxidative stress and inflammation in an atopic dermatitis model while restoring immune balance, suggesting a promising treatment strategy.

This review discusses recent findings on the mechanisms driving bullous pemphigoid, highlighting epitope spreading and the roles of regulatory T cells, and reports no new experimental results.

This study systematically reviewed literature on paradoxical reactions during biologic treatments for psoriasis, identifying immune dysregulation mechanisms and diverse clinical manifestations, highlighting that mild cases often respond well to topical treatments, while severe cases may require switching to different IL-23 inhibitors.

This study highlights the underexplored allergenic potential of Trichophyton rubrum, a dermatophyte, which can trigger IgE-mediated allergic reactions and a Th2 immune response shift, underscoring the need for its inclusion in diagnostic panels and further research for treating chronic mycoses and related allergies.

This study observed mixed responses to dupilumab in patients with both atopic dermatitis and alopecia areata, suggesting a potential role for Th2 axis dysregulation in alopecia areata.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

This study demonstrates that T-cell responses in extensive alopecia areata scalp may be aberrantly regulated, with reduced cytokine production but activated phenotype, providing insight into the disease's immune mechanisms.

This review explores the emerging roles of NK cells in various diseases, including allergies and skin conditions, and reports no new clinical results while indicating NK cell involvement in immune processes.

Asthma may increase the risk of alopecia areata.

This review analyzes the interplay between atopic dermatitis and alopecia areata, suggesting that epidermal barrier dysfunction and genetic predispositions exacerbate both conditions through immune responses.

This study found that alopecia areata patients in Central Europe with comorbid chronic inflammatory disorders, especially atopic dermatitis, bronchial asthma, or Hashimoto's thyroiditis, had an increased likelihood of experiencing early-onset, severe, or prolonged disease compared to those without such comorbidities.

The study investigated immune cell patterns around the hair follicle infundibulum in androgenetic alopecia, revealing significant differences in immune signatures between patients with AGA and control donors, specifically noting an enrichment of CD4 cells in the patient group.

This study found that acne lesions and nonlesional skin in mild-to-moderate acne patients showed significant Th17-skewing and increased antimicrobials, suggesting systemic targets like IL-17/IL-23/IL-36 could be therapeutic.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This study found that IL18 signaling plays a crucial role in the homing and retention of mature regulatory T cells in the mouse thymus, primarily by upregulating the chemokine receptor CCR6.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.